Adaptive Biotechnologies (ADPT) Assets Average (2019 - 2026)

Adaptive Biotechnologies has disclosed Assets Average across 8 years of filings, most recently posting $573.3 million for Q2 2026.

• In Q2 2026, Assets Average rose 13.81% year-over-year to $573.3 million; the TTM figure through Jun 2026 stood at $573.3 million (up 13.81% YoY), while the FY2025 annual figure was $526.1 million, down 12.36% from the prior year.
• Assets Average came in at $573.3 million for Q2 2026 at Adaptive Biotechnologies, up from $509.3 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $890.8 million in Q1 2022 to a low of $493.6 million in Q3 2025.
• Average Assets Average over 5 years is $663.5 million, with a median of $621.7 million recorded in 2024.
• Year-over-year, Assets Average fell 22.86% in 2024 and climbed 13.81% in 2026.
• Over 5 years, Assets Average stood at $870.4 million in 2022, then slipped by 20.8% to $689.4 million in 2023, then decreased by 20.38% to $548.9 million in 2024, then declined by 8.61% to $501.7 million in 2025, then advanced by 14.28% to $573.3 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $573.3 million in Q2 2026, $509.3 million in Q1 2026, and $501.7 million in Q4 2025.